Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes
oleh: Guanlan Xu, Tiffany D. Grimes, Truman B. Grayson, Junqin Chen, Lance A. Thielen, Hubert M. Tse, Peng Li, Matt Kanke, Tai-Tu Lin, Athena A. Schepmoes, Adam C. Swensen, Vladislav A. Petyuk, Fernando Ovalle, Praveen Sethupathy, Wei-Jun Qian, Anath Shalev
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2022-03-01 |
Deskripsi
Oral verapamil lowers inflammatory markers and daily insulin needs in subjects with type 1 diabetes and helps preserve pancreatic beta cell function for at least two years. In this context, serum chromogranin A provides a promising therapy marker.